Clinical Trials

    An interventional efficacy and safety Phase 3 double-blind 2-arm study to investigate IV followed by oral fosmanogepix compared with IV caspofungin followed by oral fluconazole in adult participants with candidemia and/or invasive candidiasis.

    Investigator: Eleftherios Mylonakis

    Study Coordinator: Tilemachos Koutouratsas

    Status: Enrolling

    ClinicalTrials.gov Number: NCT05421858

    Phone: 281.989.9080

    Protocol Number: PRO00038291

    Description


    Fosmanogepix (previously PF-07842805 or APX001), a novel fungal Gwt1 inhibitor, is being investigated as an IV and oral treatment in invasive fungal infections (IFIs). The current study aims to investigate the efficacy and safety of fosmanogepix versus an established regimen of IV caspofungin followed by oral fluconazole for the treatment of adult patients with candidemia and/or invasive candidiasis.